Literature DB >> 21163929

Noxa mediates p18INK4c cell-cycle control of homeostasis in B cells and plasma cell precursors.

Jamieson Bretz1, Josefina Garcia, Xiangao Huang, Lin Kang, Yang Zhang, Kai-Michael Toellner, Selina Chen-Kiang.   

Abstract

Inhibition of Cdk4/Cdk6 by p18(INK4c) (p18) is pivotal for generation of noncycling immunoglobulin (Ig)-secreting plasma cells (PCs). In the absence of p18, CD138(+) plasmacytoid cells continue to cycle and turnover rapidly, suggesting that p18 controls PC homeostasis. We now show that p18 selectively acts in a rare population of rapidly cycling CD138(hi)/B220(hi) intermediate PCs (iPCs). While retaining certain B-cell signatures, iPCs are poised to differentiate to end-stage PCs although the majority undergo apoptosis. p18 is dispensable for the development of the PC transcriptional circuitry, and Blimp-1 and Bcl-6 are expressed fully and mutually exclusively in individual iPCs. However, a minor proportion of iPCs express both, and they are preferentially protected by p18 or Bcl-xL overexpression, consistent with expansion of the iPC pool by Bcl-xL overexpression, or loss of proapoptotic Bim or Noxa. Expression of Noxa is induced during B-cell activation, peaks in iPCs, and selectively repressed by p18. It is required to promote apoptosis of cycling B cells, especially in the absence of p18. These findings define the first physiologic function for Noxa and suggest that by repressing Noxa, induction of G₁ arrest by p18 bypasses a homeostatic cell-cycle checkpoint in iPCs for PC differentiation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21163929      PMCID: PMC3062327          DOI: 10.1182/blood-2010-06-288027

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  46 in total

Review 1.  How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?

Authors:  Jerry E Chipuk; Douglas R Green
Journal:  Trends Cell Biol       Date:  2008-03-07       Impact factor: 20.808

2.  Frequent aberrant immunoglobulin gene rearrangements in pro-B cells revealed by a bcl-xL transgene.

Authors:  W Fang; D L Mueller; C A Pennell; J J Rivard; Y S Li; R R Hardy; M S Schlissel; T W Behrens
Journal:  Immunity       Date:  1996-03       Impact factor: 31.745

3.  The phenotype and fate of the antibody-forming cells of the splenic foci.

Authors:  K G Smith; T D Hewitson; G J Nossal; D M Tarlinton
Journal:  Eur J Immunol       Date:  1996-02       Impact factor: 5.532

4.  Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18(INK4c) and IL-6.

Authors:  L Morse; D Chen; D Franklin; Y Xiong; S Chen-Kiang
Journal:  Immunity       Date:  1997-01       Impact factor: 31.745

5.  Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function.

Authors:  H W Mittrücker; T Matsuyama; A Grossman; T M Kündig; J Potter; A Shahinian; A Wakeham; B Patterson; P S Ohashi; T W Mak
Journal:  Science       Date:  1997-01-24       Impact factor: 47.728

6.  Control of inflammation, cytokine expression, and germinal center formation by BCL-6.

Authors:  A L Dent; A L Shaffer; X Yu; D Allman; L M Staudt
Journal:  Science       Date:  1997-04-25       Impact factor: 47.728

7.  Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.

Authors:  Patricia Gomez-Bougie; Soraya Wuillème-Toumi; Emmanuelle Ménoret; Valérie Trichet; Nelly Robillard; Moreau Philippe; Régis Bataille; Martine Amiot
Journal:  Cancer Res       Date:  2007-06-01       Impact factor: 12.701

8.  bcl-x exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice.

Authors:  D A Grillot; R Merino; J C Pena; W C Fanslow; F D Finkelman; C B Thompson; G Nunez
Journal:  J Exp Med       Date:  1996-02-01       Impact factor: 14.307

9.  Deletions of CDKN2C in multiple myeloma: biological and clinical implications.

Authors:  Paola E Leone; Brian A Walker; Matthew W Jenner; Laura Chiecchio; Gianpaolo Dagrada; Rebecca K M Protheroe; David C Johnson; Nicholas J Dickens; Jose Luis Brito; Monica Else; David Gonzalez; Fiona M Ross; Selina Chen-Kiang; Faith E Davies; Gareth J Morgan
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

10.  Immunoglobulin switch transcript production in vivo related to the site and time of antigen-specific B cell activation.

Authors:  K M Toellner; A Gulbranson-Judge; D R Taylor; D M Sze; I C MacLennan
Journal:  J Exp Med       Date:  1996-05-01       Impact factor: 14.307

View more
  12 in total

1.  Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma.

Authors:  Sarah T Wilkinson; Kristie A Vanpatten; Diane R Fernandez; Patrick Brunhoeber; Karl E Garsha; Betty J Glinsmann-Gibson; Thomas M Grogan; Julie Teruya-Feldstein; Lisa M Rimsza
Journal:  Blood       Date:  2011-12-13       Impact factor: 22.113

2.  BCR-signaling-induced cell death demonstrates dependency on multiple BH3-only proteins in a murine model of B-cell lymphoma.

Authors:  M J Carter; K L Cox; S J Blakemore; Y D Bogdanov; L Happo; C L Scott; A Strasser; G K Packham; M S Cragg
Journal:  Cell Death Differ       Date:  2015-07-17       Impact factor: 15.828

3.  Coordinated regulation of lymph node vascular-stromal growth first by CD11c+ cells and then by T and B cells.

Authors:  Susan Chyou; Fairouz Benahmed; Jingfeng Chen; Varsha Kumar; Sha Tian; Martin Lipp; Theresa T Lu
Journal:  J Immunol       Date:  2011-10-26       Impact factor: 5.422

4.  Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.

Authors:  Xiangao Huang; Maurizio Di Liberto; David Jayabalan; Jun Liang; Scott Ely; Jamieson Bretz; Arthur L Shaffer; Tracey Louie; Isan Chen; Sophia Randolph; William C Hahn; Louis M Staudt; Ruben Niesvizky; Malcolm A S Moore; Selina Chen-Kiang
Journal:  Blood       Date:  2012-06-20       Impact factor: 22.113

Review 5.  Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy.

Authors:  Kevin Wang; Xiangao Huang; Maurizio Di Liberto; Selina Chen-Kiang
Journal:  Hematol Oncol Clin North Am       Date:  2020-08-01       Impact factor: 3.722

6.  Estrogen-mediated upregulation of Noxa is associated with cell cycle progression in estrogen receptor-positive breast cancer cells.

Authors:  Wensheng Liu; Wendy M Swetzig; Rajesh Medisetty; Gokul M Das
Journal:  PLoS One       Date:  2011-12-22       Impact factor: 3.240

7.  Stability of building gene regulatory networks with sparse autoregressive models.

Authors:  Jagath C Rajapakse; Piyushkumar A Mundra
Journal:  BMC Bioinformatics       Date:  2011-11-30       Impact factor: 3.169

Review 8.  A replicative self-renewal model for long-lived plasma cells: questioning irreversible cell cycle exit.

Authors:  Reuben M Tooze
Journal:  Front Immunol       Date:  2013-12-18       Impact factor: 7.561

9.  Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles' heel in mantle cell lymphoma.

Authors:  M A Dengler; A Weilbacher; M Gutekunst; A M Staiger; M C Vöhringer; H Horn; G Ott; W E Aulitzky; H van der Kuip
Journal:  Cell Death Dis       Date:  2014-01-23       Impact factor: 8.469

10.  Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1.

Authors:  David Chiron; Peter Martin; Maurizio Di Liberto; Xiangao Huang; Scott Ely; Brian J Lannutti; John P Leonard; Christopher E Mason; Selina Chen-Kiang
Journal:  Cell Cycle       Date:  2013-05-15       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.